Lupin gets USFDA nod for Hydrocortisone Valerate cream
22 August 2019 | News
It is indicated for the relief of the Inflammatory and pruritic manifestations of corticosteroid responsive dermatoses in adult patients
Pharma major Lupin Limited (Lupin) announced that it has received approval for its Hydrocortisone Valerate Cream USP, 0.2% from the United States Food and Drug Administration (U.S. FDA).
Lupin’s Hydrocortisone Valerate Cream USP, 0.2%, is the generic version of Westcort® Cream, 0.2%, of Sun Pharmaceutical Industries, Inc. It is indicated for the relief of the Inflammatory and pruritic manifestations of corticosteroid responsive dermatoses in adult patients.
Hydrocortisone Valerate Cream USP, 0.2%, (RLD: Westcort®) had an annual sales of approximately USD 15 million in the US (IQVIA MAT March 2019).
